Induced pluripotent stem cell-derived hepatocytes reveal TCA cycle disruption and the potential basis for triheptanoin treatment for malate dehydrogenase 2 deficiency. The gene discussed is MDH2; the disease is hyperinsulinemic hypoglycemia, familial, 4.